European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
HAMPTON, N.J., May 17, 2017 -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that clinical results from the single-agent cohort of the Phase 2 study of glembatumumab vedotin in patients with metastatic melanoma and the Phase 1 dose-escalation study of varlilumab and nivolumab in multiple solid tumors, will be presented in oral presentations at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 2-6, 2017 in Chicago. Information in the abstracts is current as of the time of submission in February 2017.
- Abstract #109: “A Phase 2 study of glembatumumab vedotin, an antibody-drug conjugate (ADC) targeting gpNMB, in advanced melanoma.” Patrick A. Ott, M.D., Ph.D., Clinical Director of Dana-Farber Cancer Institute’s Melanoma Center and its Center for Immuno-Oncology, and Assistant Professor of Medicine at Harvard Medical School, will present results during the Clinical Science Symposium “Hitting the Target: Antibody-Drug Conjugates,” which begins on Monday, June 5, 2017 at 9:45 a.m. CDT.
- Abstract #3007: “Clinical results with combination of anti-CD27 agonist antibody, varlilumab, with anti-PD1 antibody nivolumab in advanced cancer patients.” Rachel E. Sanborn, M.D., co-director of the Providence Thoracic Oncology Program at Providence Cancer Center in Portland, Ore., will present results during the session “Developmental Therapeutics—Immunotherapy,” which begins on Monday, June 5, 2017 at 1:15 p.m. CDT.
About Celldex Therapeutics, Inc.
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline includes antibodies, antibody-drug conjugates and other protein-based therapeutics derived from a broad set of complementary technologies which have the ability to engage the human immune system and/or directly inhibit tumors to treat specific types of cancer or other diseases. Visit www.celldex.com.
Company Contact Sarah Cavanaugh Vice President of Investor Relations & Corp Communications Celldex Therapeutics, Inc. (781) 433-3161 [email protected] Charles Liles Associate Director of Investor Relations & Corp Communications Celldex Therapeutics, Inc. (781) 433-3107 [email protected] Media Contact Dan Budwick Founder, 1AB Media (973) 271-6085 [email protected]
